CTI BioPharma Corp (CTIC) Expected to Announce Earnings of -$0.28 Per Share
Wall Street analysts predict that CTI BioPharma Corp (NASDAQ:CTIC) will report earnings per share of ($0.28) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for CTI BioPharma’s earnings, with estimates ranging from ($0.32) to ($0.23). CTI BioPharma posted earnings per share of ($0.30) in the same quarter last year, which indicates a positive year over year growth rate of 6.7%. The company is scheduled to issue its next earnings report on Wednesday, March 6th.
According to Zacks, analysts expect that CTI BioPharma will report full-year earnings of ($0.85) per share for the current fiscal year, with EPS estimates ranging from ($0.91) to ($0.78). For the next fiscal year, analysts forecast that the business will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.09) to ($0.74). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover CTI BioPharma.
CTI BioPharma (NASDAQ:CTIC) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). CTI BioPharma had a negative net margin of 361.97% and a negative return on equity of 85.84%. The company had revenue of $0.72 million for the quarter, compared to analyst estimates of $0.60 million.
Several institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. increased its position in shares of CTI BioPharma by 4.5% during the first quarter. BlackRock Inc. now owns 433,784 shares of the biopharmaceutical company’s stock valued at $1,691,000 after acquiring an additional 18,666 shares during the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of CTI BioPharma in the second quarter valued at approximately $137,000. Rhumbline Advisers purchased a new position in shares of CTI BioPharma in the second quarter valued at approximately $243,000. Alps Advisors Inc. purchased a new position in shares of CTI BioPharma in the second quarter valued at approximately $419,000. Finally, Renaissance Technologies LLC boosted its stake in shares of CTI BioPharma by 12.3% in the second quarter. Renaissance Technologies LLC now owns 773,445 shares of the biopharmaceutical company’s stock valued at $3,852,000 after purchasing an additional 84,500 shares during the period. Institutional investors and hedge funds own 59.22% of the company’s stock.
Shares of CTIC traded down $0.09 during trading on Wednesday, reaching $1.62. 127,121 shares of the company traded hands, compared to its average volume of 160,434. CTI BioPharma has a twelve month low of $1.55 and a twelve month high of $5.36. The stock has a market cap of $97.42 million, a PE ratio of -1.31 and a beta of -0.43. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.58 and a quick ratio of 3.58.
About CTI BioPharma
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.
Featured Article: What are the benefits of a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.